Advanced search
Publication Cover
Current Medical Research and Opinion Volume 35, 2019 - Issue 5
Submit an article Journal homepage
1,994
Views
16
CrossRef citations to date
0
Altmetric
Diabetes

Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study

Thorsten OttoLilly Deutschland GmbH, Bad Homburg, Germany;
,
Melissa MylandIQVIA Centre of Excellence for Retrospective Studies, London, UK;
,
Heike JungLilly Deutschland GmbH, Bad Homburg, Germany;
,
Jeremie LebrecLilly Deutschland GmbH, Bad Homburg, Germany;
,
Hartmut RichterIQVIA, Frankfurt am Main, Germany;
&
Kirsi NorrbackaEli Lilly Finland, Helsinki, FinlandCorrespondence[email protected]
Pages 893-901 | Received 07 Jun 2018, Accepted 16 Oct 2018, Published online: 14 Nov 2018

Figures & data

Figure 1. Overview of study design for Cohorts 1 and 2 (385 × 288 mm; 96 × 96 DPI).

Figure 1. Overview of study design for Cohorts 1 and 2 (385 × 288 mm; 96 × 96 DPI).

Table 1. Baseline characteristics for Cohort 1.

Table 2. Index therapy treatment modifications over the 12-month follow-up period, Cohort 1.

Figure 2. K-M for end of persistence, Cohort 1 (282 × 99 mm; 96 × 96 DPI).

Figure 2. K-M for end of persistence, Cohort 1 (282 × 99 mm; 96 × 96 DPI).

Table 3. Baseline characteristics for Cohort 2.

Table 4. Index therapy treatment modifications over the 12-month follow-up period, Cohort 2.

Figure 3. K-M for end of persistence, Cohort 2 (282 × 100 mm; 96 × 96 DPI).

Figure 3. K-M for end of persistence, Cohort 2 (282 × 100 mm; 96 × 96 DPI).
Supplemental material

Supplemental Material

Download TIFF Image (146.9 KB)

Supplemental Material

Download TIFF Image (153.4 KB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Type 2 diabetes: A 21st century epidemic.
Source: Elsevier BV
Ermittlung der tatsächlichen Tagesdosierung von Liraglutid (PDD) unter realen Versorgungsbedingungen im Hinblick auf die Berechnung von Tagestherapiekosten
Source: Georg Thieme Verlag KG
Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Source: Elsevier BV
Comparative effectiveness of exenatide once-weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta-analysis of observational studies.
Source: Wiley
Praxisempfehlungen DDG/DGIM
Source: Georg Thieme Verlag KG
Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies.
Source: Informa UK Limited
Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data
Source: Elsevier BV
The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide
Source: Informa Healthcare
Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study
Source: Taylor & Francis
Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
Source: Informa Healthcare
Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
Source: Research Square Platform LLC
Healthcare costs of Type 2 diabetes in Germany.
Source: Wiley
Increased persistency in medication use by U.S. Medicare beneficiaries with diabetes is associated with lower hospitalization rates and cost savings.
Source: American Diabetes Association
8. Pharmacologic Approaches to Glycemic Treatment
Source: American Diabetes Association
Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.
Source: Informa UK Limited
ROOTS: A multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients.
Source: Elsevier BV
Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review.
Source: Springer Science and Business Media LLC

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.